Lycia Therapeutics, Inc. LYCA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -9.60M | -9.60M | |||
| Total Depreciation and Amortization | 540.50K | 540.50K | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -17.00K | -17.00K | |||
| Change in Net Operating Assets | 12.00K | 12.00K | |||
| Cash from Operations | -9.06M | -9.06M | |||
| Capital Expenditure | -- | -- | |||
| Sale of Property, Plant, and Equipment | 35.50K | 35.50K | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -7.47M | -7.47M | |||
| Cash from Investing | -7.44M | -7.44M | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | 37.55M | 37.55M | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -216.00K | -216.00K | |||
| Cash from Financing | 37.34M | 37.34M | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 20.84M | 20.84M | |||